Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC leukemia cooperative group phase II study
- 30 November 1988
- journal article
- Published by Elsevier BV in European Journal of Cancer and Clinical Oncology
- Vol. 24 (11), 1721-1725
- https://doi.org/10.1016/0277-5379(88)90073-9
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Results of induction and consolidation treatment with intermediate and high‐dose cytosine arabinoside and m‐Amsa of patients with poor‐risk acute myelogeneous leukaemiaEuropean Journal of Haematology, 1988
- RESULTS OF INDUCTION AND CONSOLIDATION TREATMENT WITH INTERMEDIATE AND HIGH‐DOSE ARA‐C AND m‐AMSA CONTAINING REGIMENS IN PATIENTS WITH PRIMARILY FAILED OR RELAPSED ACUTE LEUKEMIA AND NON‐HODGKIN'S LYMPHOMAScandinavian Journal of Haematology, 1986
- High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia.Journal of Clinical Oncology, 1985
- High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia.Journal of Clinical Oncology, 1984
- The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of acute non-lymphocytic leukaemia in relapseBritish Journal of Haematology, 1984
- High-dose cytosine arabinoside therapy for refractory leukemiaBlood, 1983
- High dose cytosine arabinoside (HDARAC) in refractory acute leukemiaCancer, 1979